Oncological Safety of Residual Tumor Size‐Tailored Breast‐Conserving Surgery After Neoadjuvant Chemotherapy Response
World Journal of Surgery · 2025
DOI: 10.1002/wjs.70164 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Surgery, 2025. Verfasst von Nagm Eldin Abu Elnga und 3 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery Department, Faculty of Medicine, Assiut University, Assiut, Egypt. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Breast Neoplasms, Mastectomy, Segmental. Die Arbeit nennt 24 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Neoadjuvant chemotherapy (NACT) facilitates breast‐conserving surgery (BCS) in patients with initially inoperable breast cancer by reducing tumor size. This study assesses the oncological safety and efficacy of BCS tailored to post‐NACT residual tumor size in patients with favorable responses.
Methods
In a prospective cohort study conducted at Assiut University Hospitals, Egypt (October 2020–April 2024), 100 female breast cancer patients with partial or complete response to NACT underwent oncoplastic BCS. Outcomes included local recurrence‐free survival (LRFS), disease‐free survival (DFS), overall survival (OS), and complication rates, assessed over a mean follow‐up of 38 months with statistical analysis using Kaplan‐Meier survival estimates and univariate Cox regression.
Results
Patients had a mean age of 44 years, with a median follow‐up of 38 months. Pre‐NACT, 92% had T2/T3 tumors downstaged to 74% clinical T0/T1 post‐NACT. Intraoperative frozen section ensured a 0% positive margin rate and 0% re‐excision rate, with all margins confirmed negative on final pathology. The LRFS rates were 96% and 89% at 36 months. The DFS rate was 82% at 36 months. Triple‐negative tumors had a higher risk of local recurrence. HER2+ cases were responsible for all distant metastases, with one case in the brain occurring at 11 months. The OS rate was 97% at 36 months.
Conclusion
Resection margins adjusted to the post‐NACT tumor bed offer acceptable safety when negative margins “no ink in the tumor” achieved. The adequacy of the margins, nodal status, and molecular subtype help determine the risk of recurrence, supporting tailored adjuvant strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- General Surgery Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
ORCID-Profile: Nagm Eldin Abu Elnga
Zitieren
APA
Abu Elnga, N. E., Kotb, M. B. M., Ahmed, M. T., & Mahmoud, S. H. (2025). Oncological Safety of Residual Tumor Size‐Tailored Breast‐Conserving Surgery After Neoadjuvant Chemotherapy Response. World Journal of Surgery. https://doi.org/10.1002/wjs.70164
Vancouver
Abu Elnga NE, Kotb MBM, Ahmed MT, Mahmoud SH. Oncological Safety of Residual Tumor Size‐Tailored Breast‐Conserving Surgery After Neoadjuvant Chemotherapy Response. World Journal of Surgery. 2025. doi:10.1002/wjs.70164
BibTeX
@article{AbuElnga2025,
author = {Abu Elnga, Nagm Eldin and Kotb, Mohamed B M and Ahmed, Mustafa Thabet and Mahmoud, Samir H},
title = {Oncological Safety of Residual Tumor Size‐Tailored Breast‐Conserving Surgery After Neoadjuvant Chemotherapy Response},
journal = {World Journal of Surgery},
year = {2025},
doi = {10.1002/wjs.70164}
}
EUVIMED